Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. There would be some synergies on the commercial sales side. All rights reserved. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Here's a look at the 10 top takeover targets. Someone is "mistaken" here. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. Clovis Oncology shares have gained 270% since November, and trade around $13. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. Analysts, on average, predict over 75% upside for Crispr shares. If you have an ad-blocker enabled you may be blocked from proceeding. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Which company is going to get bought? Oncology and gene therapy were the subjects of acquisitions this year. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. The Motley Fool recommends Biogen and Gilead Sciences. Please. The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. To read this article on Zacks.com click here. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. A Roth Capital Partners analyst remarked in May of this year that he believes ACAD is on big pharmas' radar as an acquisition target. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. A report from industry analyst IQVIA suggests that "significant deal activity, both in terms of volume and value, will continue to be seen in oncology, with next-generation biological therapies such as neoantigen-directed approaches likely to attract considerable big pharma interest". Alnylam currently carries a Zacks Rank #3 (Hold). Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. However, the Company has turned down Elliott's recommendation. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Antares Pharma. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. The rumors on Obagi turned out to be correct, as the company was sold last. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Later, Bristol-Myers Squibb for $2.4B. Biotech M&A With a Slow Start in 2020: More Deals to Follow? Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. One of those stocks was. They are my opinions only. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. Any you had ideas about? Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Keep track of M&A as it happens with this database. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. The companys drug Ocaliva has been approved for primary biliary cholangitis. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. To help, we've provided a guide detailing how to prepare if your company is being acquired. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. We first began to hear acquisition rumors in Antares in late 2011. Disclosure: I am long ATRS, SLTM, ACRX. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Go and get the Biotech Investments HOT STOCK REPORT. Now, let's take a speculative twist in our discussion about acquisitions. Pharma giant Pfizer recently. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. Scott has had the most success in trading/investing in smaller cap growth companies. Cash position at the end of the fiscal year was at $1.52 billion. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Enclose phrases in quotes. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. But following Gilead's decision to acquire Kite Pharma in August of that year, the rumors died down. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). Markets. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. No. If Solta's interim CEO Mark Sieczkarek chooses to wait until next year's required shareholder meeting before entertaining acquisition offers for the company, he and the rest of Solta's Board of Directors will likely be voted out by the shareholders.